JP2020507332A5 - - Google Patents

Download PDF

Info

Publication number
JP2020507332A5
JP2020507332A5 JP2019544614A JP2019544614A JP2020507332A5 JP 2020507332 A5 JP2020507332 A5 JP 2020507332A5 JP 2019544614 A JP2019544614 A JP 2019544614A JP 2019544614 A JP2019544614 A JP 2019544614A JP 2020507332 A5 JP2020507332 A5 JP 2020507332A5
Authority
JP
Japan
Prior art keywords
cancer
protein
pharmaceutical composition
composition according
salmonella
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019544614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507332A (ja
JP7712060B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/053918 external-priority patent/WO2018149982A1/en
Publication of JP2020507332A publication Critical patent/JP2020507332A/ja
Publication of JP2020507332A5 publication Critical patent/JP2020507332A5/ja
Priority to JP2023133276A priority Critical patent/JP2023160838A/ja
Application granted granted Critical
Publication of JP7712060B2 publication Critical patent/JP7712060B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019544614A 2017-02-17 2018-02-16 新規vegfr-2ターゲット免疫療法アプローチ Active JP7712060B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023133276A JP2023160838A (ja) 2017-02-17 2023-08-18 新規vegfr-2ターゲット免疫療法アプローチ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17156718.3 2017-02-17
EP17156718 2017-02-17
PCT/EP2018/053918 WO2018149982A1 (en) 2017-02-17 2018-02-16 Novel vegfr-2 targeting immunotherapy approach

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023133276A Division JP2023160838A (ja) 2017-02-17 2023-08-18 新規vegfr-2ターゲット免疫療法アプローチ

Publications (3)

Publication Number Publication Date
JP2020507332A JP2020507332A (ja) 2020-03-12
JP2020507332A5 true JP2020507332A5 (enExample) 2021-03-25
JP7712060B2 JP7712060B2 (ja) 2025-07-23

Family

ID=58094260

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019544614A Active JP7712060B2 (ja) 2017-02-17 2018-02-16 新規vegfr-2ターゲット免疫療法アプローチ
JP2023133276A Withdrawn JP2023160838A (ja) 2017-02-17 2023-08-18 新規vegfr-2ターゲット免疫療法アプローチ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023133276A Withdrawn JP2023160838A (ja) 2017-02-17 2023-08-18 新規vegfr-2ターゲット免疫療法アプローチ

Country Status (13)

Country Link
US (1) US10980868B2 (enExample)
EP (1) EP3583200A1 (enExample)
JP (2) JP7712060B2 (enExample)
KR (2) KR20190117603A (enExample)
CN (1) CN110291187A (enExample)
AU (1) AU2018222777B9 (enExample)
BR (1) BR112019016925A2 (enExample)
CA (1) CA3050833A1 (enExample)
IL (1) IL268186A (enExample)
MX (1) MX2019009724A (enExample)
RU (1) RU2019125436A (enExample)
SG (1) SG11201907391SA (enExample)
WO (1) WO2018149982A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3310379T3 (pl) * 2015-06-18 2020-03-31 Vaximm Ag Szczepionka dna wycelowana w vegfr-2 do terapii skojarzonej
CA3109430A1 (en) * 2018-09-05 2020-03-12 Vaximm Ag Neoantigen targeting dna vaccine for combination therapy
CN113527509B (zh) * 2020-04-17 2023-09-26 深圳华大生命科学研究院 含有重组蛋白和保护蛋白的复合物在治疗肺鳞癌中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO337687B1 (no) 2011-07-08 2016-06-06 Norsk Elektro Optikk As Hyperspektralt kamera og metode for å ta opp hyperspektrale data
US9493738B2 (en) * 2011-12-22 2016-11-15 Vaximm Ag Method for producing high yield attenuated Salmonella strains
EP3603664A1 (en) 2012-07-05 2020-02-05 Vaximm AG Dna vaccine for use in pancreatic cancer patients
ES2675020T3 (es) * 2013-04-25 2018-07-05 Vaximm Ag Vectores basados en Salmonella para inmunoterapia del cáncer dirigida al gen WT1 del tumor de Wilms
SG11201604911VA (en) * 2013-12-18 2016-07-28 Vaximm Gmbh Novel msln targeting dna vaccine for cancer immunotherapy
WO2015142875A1 (en) * 2014-03-17 2015-09-24 The Trustees Of The University Of Pennsylvania Compositions and methods using modified salmonella
PL3310379T3 (pl) 2015-06-18 2020-03-31 Vaximm Ag Szczepionka dna wycelowana w vegfr-2 do terapii skojarzonej
BR112019000657A2 (pt) 2016-07-13 2019-04-24 Vaximm Ag método para produzir uma vacina de dna para imunoterapia de câncer e vacina de dna

Similar Documents

Publication Publication Date Title
JP2020511139A5 (enExample)
RU2019132253A (ru) Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака
Piper et al. Glioma stem cells as immunotherapeutic targets: advancements and challenges
Ilett et al. Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy
Weichselbaum The 46th David A. Karnofsky Memorial Award lecture: oligometastasis—from conception to treatment
JP6945301B2 (ja) Hpvおよび関連する疾病のための免疫増強治療ワクチン
RU2016129044A (ru) Новая вакцина днк, нацеленная на мезотелин, для иммунотерапии рака
Fan et al. Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity
RU2015103758A (ru) Днк-вакцина для применения у пациентов с раком поджелудочной железы
US10987432B2 (en) Therapeutic delivery and expression system, methods and uses thereof
Kang et al. Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects
Mei et al. Combining DNA vaccine and AIDA-1 in attenuated Salmonella activates tumor-specific CD4+ and CD8+ T-cell responses
JP2018517419A5 (enExample)
Zhao et al. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response
JP2020507332A5 (enExample)
RU2018101722A (ru) Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии
CN114592010A (zh) NK-CAR-MbIL-15细胞及其制备方法和应用
CN110408634B (zh) 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法
JP2023160838A (ja) 新規vegfr-2ターゲット免疫療法アプローチ
BR112021001117A2 (pt) células cancerígenas modificadas, composição farmacêutica, linha celular, métodos para fazer células cancerígenas modificadas e para estimular uma resposta imune, vetor de expressão isolado ou combinação de vetores de expressão isolados, e, uma ou mais células cancerígenas modificadas
Jia et al. The future of cancer vaccines against colorectal cancer
Kim et al. Electroporation driven delivery of both an IL-12 expressing plasmid and cisplatin synergizes to inhibit B16 melanoma tumor growth through an NK cell mediated tumor killing mechanism
RU2019112977A (ru) Днк-вакцина, нацеленная на wt1, для комбинированной терапии
Sun et al. Genetically engineered recombinant adenovirus expressing interleukin‑2 for hepatocellular carcinoma therapy
CN115804853A (zh) 包含rna分子的组合物及其在制备瘤内注射剂中的用途